Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients

NCT07752043 · clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators